Callisto Biomed
- Diagnostics
Callisto BioMed is redefining cardiovascular risk prediction. Our LipoScan micro-fluidic platform delivers a fully automated read-out of all five HDL subclasses (including HDL-2b) and sdLDL from a 5 µL finger-stick in under 90 seconds. Already NMPA-cleared and used in 20+ hospitals, it will launch under CLIA in 2025 and pursue FDA clearance in 2026.
Why it matters – specific HDL sub-fractions predict coronary events 30 % better than total HDL-C, yet routine lipid panels ignore them.
Partner value:
• Pharma/Biotech – turnkey companion & stratification test for HDL-targeted drugs and gene therapies.
• IVD Labs – desktop analyzer runs 96 samples in < 2 h and qualifies for CPT 83701 reimbursement.
• Investors – consumable model projected to exceed 1 M tests/year by Year 4 at > 60 % gross margin; raising US $5 M Series A.
Meet co-founders Odilo Mueller, PhD and David Deng, MD/PhD at BIO to shape the future of preventive cardiology.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}